SLC5A2 and osteosarcoma: Furthermore, SGLT2 inhibitor treatment in osteosarcoma cells induced IFN-β expression at the mRNA and protein levels (Fig. 5d, e) in both dose- and time-dependent manner (Fig. 5f, g).